Mission

Target Audience

Educational Objectives

CME Information

Disclosure Information

The Goal of the CME program is to plan and deliver high quality education activities for practicing physicians in order to reinforce their past learning and to disseminate new concepts and practices in medicine which may improve patient care for all medical specialties.

The audiences to be reached by its program of CME are:

Infectious Disease Physicians

Hematology Oncologists

Transplant Surgeons

Up   

Determine how therapeutic choices for invasive fungal infections can be most appropriately employed in high-risk patients.

Explore methods to improve patient outcomes, considering antifungal efficacy, spectrum of activity, safety, and cost-effectiveness.

Compare and understand the clinical uses of available antifungal agents.

Up   

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Wayne State University School of Medicine and the MedEd Group, LLC.

The Wayne State University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Wayne State University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

To receive documentation of your participation in this CME activity, complete the newsletter posttest with a passing score of 70% or higher. Full instructions for submission are included on the posttest accompanying this CME newsletter. After passing the posttest, you will be issued a CME certificate of 1.0 credit.

The disclosure policy of Wayne State University School of Medicine requires that the faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.

Pranatharthi Chandrasekar, MD, is a consultant for Enzon Pharmaceuticals, Inc., and has received honoraria/travel expenses, or other financial or material support from Enzon Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co., Inc., and Schering-Plough.

Dimitrios P. Kontoyiannis, MD, MSc, ScD, FACP, FIDSA, is on the advisory board of and is a consultant for Merck & Co., Inc., and Schering-Plough. He has received research support from Enzon Pharmaceuticals, Inc., Fujisawa/ Astellas, and Merck & Co., Inc., and has received honoraria/travel expenses or other financial or material support from Enzon Pharmaceuticals, Inc., Fujisawa/Astellas, and Merck & Co., Inc.

Up